Article Text

Download PDFPDF

Systematic review with meta analysis
Zanamivir for influenza in adults and children shows limited benefit for treatment of symptomatic influenza and no effect on relevant complications
  1. Barbara Michiels
  1. Department of Primary and Interdisciplinary Care Antwerp, University of Antwerp, Wilrijk, Belgium
  1. Correspondence to : Dr Barbara Michiels, Department of Primary and Interdisciplinary Care Antwerp, University of Antwerp, Campus Drie Eiken R3, Universiteitsplein 1, Wilrijk 2610, Belgium; barbara.michiels{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


The neuraminidase inhibitor zanamivir, administered as an inhaled powder, is approved for the prevention and treatment of influenza in adults and children older than 7 years. Previous systematic reviews (SRs) of zanamivir may have been affected by publication bias and missing data, and clinical recommendations based on such studies should be considered inadequate.1 ,2 To deal with these shortcomings, this SR and meta-analysis (an update of a Cochrane Review)3 reanalysed the prophylactic and treatment effects of zanamivir on those suffering from influenza, based on the full clinical study reports of all relevant trials provided by the manufacturer and on regulatory comments.


This review included randomised controlled trials (RCTs) testing zanamivir compared with placebo for …

View Full Text